Diabetic Foot Ulcer Wound Care: The Clinical and Billing Guide

85% of lower extremity amputations in people with diabetes are preceded by a foot ulcer. That statistic is not a background fact — it is the argument for why DFU management done right is both clinically critical and one of the highest-value services in mobile wound care.

A single DFU patient treated over a 12–16 week episode can generate $4,000–$18,000+ in Medicare reimbursement depending on wound complexity, debridement frequency, and advanced therapy use. Getting the documentation, coding, and 2026 policy changes right is the difference between collecting that revenue and writing it off.

The Wagner Classification System

Wound care documentation for DFUs should reference the Wagner classification — the system CMS auditors expect to see.

Grade	Description	Clinical Implication
0	Pre-ulcer; intact skin with risk factors	Prevention, offloading, monitoring
1	Superficial ulcer, no infection	Debridement, offloading, standard dressings
2	Deep ulcer to tendon, capsule, or bone without osteomyelitis	Aggressive debridement, consider CTP
3	Deep ulcer with osteomyelitis, abscess, or joint infection	Surgical consult, infectious disease coordination
4	Partial forefoot gangrene	Vascular surgery, amputation risk
5	Full foot gangrene	Amputation

Mobile wound care NPs typically manage Wagner 1–2, with referral to vascular surgery and podiatry for Wagner 3+.

ICD-10 Coding for DFUs: The Sequencing Rule

DFU coding has a mandatory sequencing rule. The diabetes code comes first; the ulcer site code comes second.

Most common DFU code sequence:

Condition	Primary Code	Secondary Code
Type 2 DFU, right foot	E11.621	L97.511 or L97.512 (depth-specific)
Type 2 DFU, left foot	E11.621	L97.521 or L97.522
Type 1 DFU, right foot	E10.621	L97.511 or L97.512
Type 1 DFU, left foot	E10.621	L97.521 or L97.522

L97 depth characters (6th digit):

1: Limited to breakdown of skin
2: Fat layer exposed
3: Necrosis of muscle
4: Necrosis of bone
9: Unspecified (avoid — use as last resort)

Add Z79.4 if patient is on insulin. Add Z79.84 if patient uses oral hypoglycemics. Both may apply simultaneously.

For heel/midfoot DFUs: Use L97.4- series (right heel L97.411–L97.419, left heel L97.421–L97.429).

The 30-Day Standard Care Requirement

Before any cellular and tissue-based product (CTP/skin substitute) can be applied to a DFU, Medicare requires documentation of 30 days of standard wound care with inadequate healing. This is a coverage requirement — not a billing technicality.

Standard care must include all of the following:

Appropriate sharp debridement at each visit (when indicated)
Serial measurements with dates — L×W×D at minimum weekly
Appropriate dressing selection documented with clinical rationale
Offloading — total contact cast, pneumatic walker, or equivalent documented
ABI or vascular assessment completed
Blood glucose control documented (A1C noted in record)

The 50% rule: At week 4, calculate percent area reduction: (area at week 0 − area at week 4) ÷ area at week 0. If less than 50% reduction, document this explicitly. This is the trigger for advanced therapy coverage.

2026 Skin Substitute Payment Changes: What Changed January 1

The 2026 CMS Physician Fee Schedule final rule restructured how all skin substitutes are paid. This is the most significant change in wound care reimbursement in a decade.

Before 2026: Each product paid at ASP + 6% — individual product pricing ranging from $200 to $3,000+ per square centimeter.

2026 and forward: All skin substitutes reclassified as incident-to supplies. Flat rate of $127.28/cm² regardless of product, FDA classification, or clinical complexity.

For a typical 5 cm² DFU application:

2025 reimbursement: $1,000–$15,000+ (product-dependent)
2026 reimbursement: $636.40 for product + application fee

What this means for formulary decisions: Product cost versus reimbursement math has changed completely. Any product costing more than $127.28/cm² creates a net loss. Formulary review against 2026 payment rates is urgent if not already done.

LCD withdrawal note: The proposed new LCD for skin substitutes was withdrawn before January 1, 2026. This does not affect the payment rule — the $127.28/cm² flat rate is live. Coverage for medically necessary DFU treatment continues under existing Medicare statutory standards.

CPT Codes for DFU Management

Service	Code	Rate
Selective debridement, first 20 sq cm	97597	~$82
Selective debridement, add-on	+97598	~$38
Surgical debridement, subcutaneous	11042	~$125
Surgical debridement, muscle/fascia	11043	~$195
Skin substitute application, foot (first 25 sq cm)	15275	~$185
Skin substitute application, add-on	+15276	~$118
E/M, established patient, moderate complexity	99214	~$136

Documentation Non-Negotiables

Every DFU visit note must document:

Wagner grade
Wound measurements (L×W×D, area in cm²)
Tissue composition percentages
Periwound skin condition
Offloading compliance notation
Vascular status (ABI on file, Doppler status noted)
Blood glucose or A1C referenced
Medical necessity for services rendered

Missing any of these creates audit risk for the entire episode.